Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma

Human Gene Therapy

Volumn 9, Issue 9, 1998, Pages 1303-1311

  Bowman, Laura C ^a,b   Grossmann, Michael ^a   Rill, Donna ^a   Brown, Michael ^a   Zhong, Wan Yun ^a   Alexander, Barbara ^a   Leimig, Thasia ^a   Coustan Smith, Elaine ^a   Campana, Dario ^a   Jenkins, Jesse ^a,b   Woods, Diane ^a   Brenner, Malcolm ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONOCYTOSIS; NEUROBLASTOMA; PANNICULITIS; PRURITUS;

ANIMALIA;

EID: 17344363129     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.9-1303     Document Type: Article

References (17)

1. ANDERSON, J.R., and COCCIA, P.F. (1991). Is more better? Dose intensity in neuroblastoma. J. Clin. Oncol. 9, 902-904.
2. ASHER, A.L., MULE, J.J., KASID, A., RESTIFO, N.P., SALO, J.C., REICHERT, C.M., JAFFE, G., FENDLY, B., KRIEGLER, M., and ROSENBERG, S.A. (1991). Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227-3234.
3. BLANKENSTEIN, T., QIN, Z.H., UBERLA, K., MULLER, W., ROSEN, H., VOLK, H.D., and DIAMANTSTEIN, T. (1991). Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 173, 1047-1052.
4. BOWMAN, L., GROSSMANN, M., RILL, D., BROWN, M., ZHONG, W., ALEXANDER, B., LEIMIG, T., COUSTAN-SMITH, E., CAMPANA, D., J., WOODS, D., KITCHINGMAN, G., VANIN, E., and BRENNER, M. (1998). Antitumor immune responses induced by IL2 gene-modified tumor cells in children with advanced neuroblastoma. J. Clin. Oncol. Blood (in press).
5. BRENNER, M.K., FURMAN, W.L., SANTANA, V.M., BOWMAN, L., and MEYER, W. (1992). Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Hum. Gene Ther. 3, 665-676.
6. CHEUNG, N.K., MEDOF, M.E., and MUNN, D. (1988). Immunotherapy with GD2 specific monoclonal antibodies. Progr. Clin. Biol. Res. 271, 619-632.
7. CHEUNG, N.K., BURCH, L., KUSHNER, B.H., and MUNN, D.H. (1990). Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma (NB) patients (PTS) refractory to chemotherapy: a phase II trial. [Abstract]. Proc. Annu. Meet. Am. Assoc. Cancer, Res. 31, A1705.
8. CHEUNG, N.K. (1991). Immunotherapy. Neuroblastoma as a model. Pediatr. Clin. N. Am. 38, 425-441.
9. CONNOR, J.P., GANSBACHER, B., CRONIN, K., HESTON, W., FAIR, W., and GILBOA, E. (1991). A new approach to the immunotherapy of bladder cancer using IL-2 gene transfer into MBT-2 cells. [Abstract]. Proc. Annu. Meet. Am. Assoc. Cancer Res. (1991) 32, A1475.
10. FEARON, E.R., PARDOE, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
11. FOREMAN, N.K., RILL, D.R., COUSTAN-SMITH, E., DOUGLASS, E.C., and BRENNER, M.K. (1993). Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br. J. Cancer 67, 933-938.
12. GANSBACHER, B. (1994). Clinical application of immunostimulatory gene transfer. Eur. J. Cancer 30A, 1187-1190.
13. GANSBACHER, B., HOUGHTON, A., LIVINGSTON, P., MI NASIAN, L., ROSENTHAL, F., GILBOA, E., GOLDE, D., OETTGEN, H., STEFFENS, T., YANG, S.Y., and WONG, G. (1992). A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete Interleukin-2 in patients with metastatic melanoma. Hum. Gene Ther. 3, 677-690.
14. GERMAIN, R.N. (1994). MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 76, 287.
15. TEPPER, R.I., and MULE, J.J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
16. YU, A.L., GILLIES, S.D., and REISFELD, R.A. (1991). Phase I clinical trial of Ch14.18 in patients with refractory neuroblastoma. Proc. ASCO 10, 1118 (abstract).
17. D2 oligosaccharide: target for cytotoxic T lymphocytes. J. Exp. Med. 182, 67-74.